Technetium Tc 99m Mertiatide Injection, Powder, Lyophilized, For Solution
NDC Package 65174-261-05
Package Information
Technetium Tc 99m Mertiatide injection is kit for the Preparation of Technetium Tc 99m Mertiatide Injection, after radiolabeling with technetium-99m, is indicated for use in the diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Jubilant Draximage Inc., Dba Jubilant Radiopharma, this product is identified by NDC 65174-261 and is authorized under FDA application NDA216820.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 65174 - Jubilant Draximage Inc., Dba Jubilant Radiopharma
- 65174-261 - Technetium Tc 99m Mertiatide
- 65174-261-05 - 5 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (65174-261-01)
- 65174-261 - Technetium Tc 99m Mertiatide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65174-261-05 identifies a specific commercial package of 5 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial (65174-261-01) of Technetium Tc 99m Mertiatide, a human prescription drug labeled by Jubilant Draximage Inc., Dba Jubilant Radiopharma. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains betiatide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Jubilant Draximage Inc., Dba Jubilant Radiopharma on March 31, 2023. The current certification is valid through December 31, 2026.
How is this Jubilant Draximage Inc., Dba Jubilant Radiopharma product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65174026105. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.